Effects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 8, Issue 2, 2002, Pages 233-236

  Zheng, Ning ^a   Ye, Sheng Long ^a   Sun, Rui Xia ^a   Zhao, Yan ^a   Tang, Zhao You ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLACETIC ACID; PHENYLALANINE METHYL ESTER;

ADHERENT CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LYMPHOCYTE SUBPOPULATION; LYMPHOKINE ACTIVATED KILLER CELL; MONOCYTE; MONONUCLEAR CELL; PERIPHERAL CIRCULATION; PHENOTYPE; STATISTICAL SIGNIFICANCE; SUPERNATANT; THAWING; TUMOR CELL LINE;

EID: 0036235327     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v8.i2.233     Document Type: Article

References (40)

1. Biotherapy of tumor
2. Immunology and immunotherapy of human cancer: Present concepts and clinical developments
3. Recent advances in immunotherapy and monoclonal antibody treatment of cancer
4. Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer
5. Biotherapy of hepatocellular carcinoma
6. Adoptive cellular therapy
7. Cells and cytokines in immunotherapy and gene therapy of cancer
8. Adoptive immunotherapy of advanced solid tumors: An eight year clinical experience
9. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells
10. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic
11. Supplementation with selenium augments the functions of natural killer and lymphokine-activated killer cells
12. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells
13. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients
14. Tissue distribution of adoptively transferred adherent LAK cells: Role of the route of administration
15. Biologic effects of the adoptive transfer of cells depleted of monocytes with L-phenylalanine methyl ester
16. Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumour cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma
17. Role of function-associated molecules in target cell lysis: Analysis of rat adherent lymphokine-activated killer cells
18. Differential effect of cryopreservation on natural killer cell and lymphokine-activated killer cell activities
19. Effects of cryopreservation on immune responses. VIII. Enhanced secretion of interferon-γ by frozen human peripheral blood mononuclear cells
20. Discrimination between NK and LAK cytotoxic activity of murine spleen cells by MTT assay: Differential inhibition of PGE2 and EDTA
21. Tumor-induced immunosuppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine
22. The potential for monocyte-mediated immunotherapy during infection and malignancy. Part I: Apoptosis induction and cytotoxic mechanisms
23. Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin
24. Resistance of macrophages to the suppressive effect of interleukin-10 following thermal injury
25. Lymphokine release from human lymphomononuclear cells after co-culture with isolated pancreatic islets: Effects of islet species, long-term culture, and monocyte-macrophage cell removal
26. Comparison of the effects of immunosuppressive factors from newly established colon carcinoma cell cultures on human lymphocyte proliferation and cytokine secretion
27. The role of lipocortin I in macrophage-mediated immunosuppression in tumor-bearing mice
28. The inhibition of lymphokine-activated killer cells in acute myeloblastic leukemia is mediated by TGF-β1
29. T cells and tumors
30. Current problems in the development of specific immunotherapeutic approaches to cancer
31. Suppression of immune surveillance in melanoma
32. Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients
33. Different susceptibility of murine hemopoietic cells and lymphocytes to freezing-thawing process
34. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers
35. Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma
36. Decrease of breast cancer cell invasiveness by sodium phenyloacetate (NaPa) is associated with an increased expression of adhesive molecules
37. Suppression of tumourigenicity, and induction of differentiation of the canine mammary tumor cell line MCM-B2 by sodium phenylacetate
38. Sodium phenylacetate modulates the synthesis of autocrine and peregrine growth factors secreted by breast cancer cell lines
39. Phase I study of phenylacetate administered twice daily to patients with cancer
40. Enhancement of tumor immunogenicity by phenylacetate and derivatives: Changes in surface antigens and tumor-derived immunosuppressive factors